AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34389930 — intervention group
Group type: COMPARATOR
Intervention: Self-Measured Blood Glucose (SMBG)
Number of subjects: 2623
Study 34389930 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch pump
Number of subjects: 2623
Study 34389930 — intervention group
Group type: COMPARATOR
Intervention: Insulin pumps and CGM
Number of subjects: 2623
Study 34390050 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased heart rate (HR) during task performance
Number of subjects: 51
Study 34390050 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased heart rate variability (HRV) during task performance
Number of subjects: 51
Study 34390338 — intervention group
Group type: EXPERIMENTAL
Intervention: DR9/DR9 genotype
Number of subjects: 237
Study 34390338 — intervention group
Group type: COMPARATOR
Intervention: Non-DR9/DR9 carriers
Number of subjects: 237
Study 34390394 — intervention group
Group type: EXPERIMENTAL
Intervention: Children and adolescents with SM
Number of subjects: 28
Study 34390394 — intervention group
Group type: COMPARATOR
Intervention: Controls without SM
Number of subjects: 28
Study 34390869 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene replacement therapy administered intravitreally in a phase I/IIa trial
Number of subjects: 0
Study 34390869 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene replacement therapy
Number of subjects: 0
Study 34391035 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive patients
Number of subjects: 62
Study 34391035 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 negative patients
Number of subjects: 62
Study 34391384 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria-based rehabilitation program including strength and reactive strength targets
Number of subjects: 60
Study 34391384 — intervention group
Group type: COMPARATOR
Intervention: Previously successful rehabilitation program
Number of subjects: 60
Study 34391384 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria-based rehabilitation program
Number of subjects: 60
Study 34391393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol 600 mg (300 mg BID)
Number of subjects: 130
Study 34391393 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 4 mg (2 mg BID)
Number of subjects: 130
Study 34391399 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TGIF expression levels
Number of subjects: 1197
Study 34391399 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TGIF expression levels in ER-positive BC patients
Number of subjects: 1197
Study 34391399 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TGIF expression levels in HER2-negative subgroup
Number of subjects: 1197
Study 34391408 — intervention group
Group type: COMPARATOR
Intervention: No dementia (MMSE 28-30)
Number of subjects: 137
Study 34391408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MMSE 25-27)
Number of subjects: 137
Study 34391408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild dementia (MMSE 18-24)
Number of subjects: 137
Study 34391408 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dementia (MMSE 10-17)
Number of subjects: 137
Study 34391408 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe dementia (MMSE < 10)
Number of subjects: 137
Study 34391480 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 187004 (2.5-360 mg)
Number of subjects: 72
Study 34391480 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 187004 (5 mg)
Number of subjects: 72
Study 34391480 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 187004 (160 mg)
Number of subjects: 72
Study 34391480 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 187004 (10 mg)
Number of subjects: 72
Study 34391480 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 187004 (360 mg)
Number of subjects: 72
Study 34391480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 34391745 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Oxygen Uptake (pVO2) measurement after LVAD implantation
Number of subjects: 450
Study 34391791 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-sensitive cardiac troponin I (hs-cTnI) measurement at admission, diagnostic cut-off <3 ng/L
Number of subjects: 1370
Study 34391791 — intervention group
Group type: EXPERIMENTAL
Intervention: Single hs-cTnI measurement at admission
Number of subjects: 1370
Study 34391922 — intervention group
Group type: EXPERIMENTAL
Intervention: mt-HBT
Number of subjects: 136
Study 34391922 — intervention group
Group type: COMPARATOR
Intervention: AFP (20 ng/mL or greater)
Number of subjects: 136
Study 34391922 — intervention group
Group type: COMPARATOR
Intervention: GALAD (-0.63 or greater)
Number of subjects: 136
Study 34392187 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg orally twice daily
Number of subjects: 20
Study 34392257 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT responders without VT/VF occurrence
Number of subjects: 1308
Study 34392257 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT nonresponder patients who suffered VT/VF
Number of subjects: 1308
Study 34392257 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT nonresponder patients without VT/VF occurrence
Number of subjects: 1308
Study 34392257 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT responders
Number of subjects: 1308
Study 34392310 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum DHA levels during the first 28 postnatal days
Number of subjects: 90
Study 34392310 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum AA levels during the first 28 postnatal days
Number of subjects: 90
Study 34392333 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE thoracic aortic devices for DTAA repair
Number of subjects: 310
Study 34392453 — intervention group
Group type: EXPERIMENTAL
Intervention: GT0918 (500 mg QD)
Number of subjects: 18
Study 34392637 — intervention group
Group type: EXPERIMENTAL
Intervention: Double hydrashift assay
Number of subjects: 3
Study 34392637 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-MRD assay
Number of subjects: 3
Study 34392819 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal CMV seroprevalence
Number of subjects: 6729
Study 34392819 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital CMV (cCMV) prevalence
Number of subjects: 6729
Study 34392819 — intervention group
Group type: EXPERIMENTAL
Intervention: cCMV infection in newborns from seropositive mothers
Number of subjects: 6729
Study 34392819 — intervention group
Group type: EXPERIMENTAL
Intervention: cCMV infection in newborns from seronegative mothers
Number of subjects: 6729
Study 34393061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib and Pembrolizumab
Number of subjects: 43
Study 34393139 — intervention group
Group type: EXPERIMENTAL
Intervention: with-COVID-19 group (132 patients)
Number of subjects: 265
Study 34393139 — intervention group
Group type: EXPERIMENTAL
Intervention: with-COVID-19 group (subgroups)
Number of subjects: 265
Study 34393139 — intervention group
Group type: COMPARATOR
Intervention: pre-COVID-19 group (133 patients)
Number of subjects: 265
Study 34393192 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class analysis based on the Edmonton Symptom Assessment System measuring nine symptoms on a scale of 0-10.
Number of subjects: 0
Study 34393192 — intervention group
Group type: EXPERIMENTAL
Intervention: Membership in the high symptom burden latent subgroup.
Number of subjects: 0
Study 34393192 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults between 65 and 74 years.
Number of subjects: 0
Study 34393192 — intervention group
Group type: EXPERIMENTAL
Intervention: High symptom burden.
Number of subjects: 0
Study 34393199 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable prediction model for persistent NSDs
Number of subjects: 384
Study 34393199 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with neurosensory recovery
Number of subjects: 384
Study 34393199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity and QoL analysis
Number of subjects: 384
Study 34393512 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 and QLQ-LC29 questionnaires
Number of subjects: 81
Study 34393512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hornheide Screening Instrument (HSI)
Number of subjects: 81
Study 34393512 — intervention group
Group type: COMPARATOR
Intervention: EORTC questionnaires as screening instrument
Number of subjects: 81
Study 34393512 — intervention group
Group type: EXPERIMENTAL
Intervention: HSI
Number of subjects: 81
Study 34393800 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (doses not specified)
Number of subjects: 0
Study 34393800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no corticosteroid treatment)
Number of subjects: 0
Study 34394195 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis of A-FAT and GF-FAT using BeadChip Methylation Array.
Number of subjects: 0
Study 34394195 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation sites in adipose tissue.
Number of subjects: 0
Study 34394782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol 5/5 µg fixed dose combination for 6 weeks
Number of subjects: 94
Study 34394782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol treatment
Number of subjects: 94
Study 34394947 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of perioperative complications
Number of subjects: 912
Study 34394947 — intervention group
Group type: COMPARATOR
Intervention: Absence of perioperative complications
Number of subjects: 912
Study 34394947 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative complications
Number of subjects: 912
Study 34395277 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative systemic treatment
Number of subjects: 1067
Study 34395277 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 1067
Study 34395457 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34395487 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime dry fasting
Number of subjects: 0
Study 34395560 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD) implantation
Number of subjects: 0
Study 34395684 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ACL repair (augmented or nonaugmented) plus rehabilitation
Number of subjects: 172
Study 34395684 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg hop limb symmetry index <90% at 4 years
Number of subjects: 172
Study 34395684 — intervention group
Group type: COMPARATOR
Intervention: Delayed ACL reconstruction (ACLR)
Number of subjects: 172
Study 34395684 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 172
Study 34395684 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps and hamstring strength, flexion and extension deficit
Number of subjects: 172
Study 34395684 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced self-reported knee function and single-leg hop performance at 4 years
Number of subjects: 172
Study 34396154 — intervention group
Group type: EXPERIMENTAL
Intervention: First COVID-19 vaccination
Number of subjects: 921
Study 34396154 — intervention group
Group type: EXPERIMENTAL
Intervention: Second COVID-19 vaccination
Number of subjects: 921
Study 34396154 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive drugs
Number of subjects: 921
Study 34396154 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 921
Study 34396157 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab with ACE inhibitors and/or beta-blockers
Number of subjects: 20
Study 34396157 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors and/or beta-blockers
Number of subjects: 20
Study 34396175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients undergoing PCI
Number of subjects: 1368
Study 34396210 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist degarelix
Number of subjects: 900
Study 34396210 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist leuprolide
Number of subjects: 900
Study 34396246 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Number of subjects: 17708
Study 34396246 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17708
Study 34396283 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants in cardiac injury pathway genes
Number of subjects: 289
Study 34396283 — intervention group
Group type: COMPARATOR
Intervention: Control patients (no specific intervention mentioned)
Number of subjects: 289
Study 34396283 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline exposure
Number of subjects: 289
Study 34396283 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for delayed anthracycline cardiotoxicity
Number of subjects: 289
Study 34397042 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive therapy consisting of esomeprazole 40 mg or rabeprazole 20 mg twice daily, amoxicillin 1,000 mg twice daily, tetracycline 500 mg 4 times daily, and furazolidone 100 mg 3 times daily for the first 7 days, followed by colloidal bismuth pectin 200 mg twice daily for another 7 days.
Number of subjects: 65
Study 34397042 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive therapy including amoxicillin, tetracycline, and furazolidone.
Number of subjects: 65
Study 34397042 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance rates to antibiotics in patients with available antimicrobial susceptibility testing results (51 patients).
Number of subjects: 65
Study 34397100 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate
Number of subjects: 2922
Study 34397100 — intervention group
Group type: COMPARATOR
Intervention: Chloral hydrate
Number of subjects: 2922
Study 34397263 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 34397263 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 34397515 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary DD surgery (including percutaneous needle fasciotomy, limited fasciectomy, or dermofasciectomy)
Number of subjects: 0
Study 34397515 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary DD surgery
Number of subjects: 0
Study 34397539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis (Vyndaqel and Vyndamax)
Number of subjects: 0
Study 34397539 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen and patisiran
Number of subjects: 0
Study 34397539 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic management and traditional therapies for congestive heart failure
Number of subjects: 0
Study 34397699 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment regimens
Number of subjects: 0
Study 34397699 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-related outcomes
Number of subjects: 0
Study 34397699 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 0
Study 34397699 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological and molecular modifications
Number of subjects: 0
Study 34397707 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of glycosylated hemoglobin (HbA1c) < 7%
Number of subjects: 20412
Study 34397707 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of blood pressure < 130/80 mm Hg
Number of subjects: 20412
Study 34397707 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of low-density lipoprotein cholesterol (LDL-C) < 2.6 mmol/l
Number of subjects: 20412
Study 34397707 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of all 3 targets (HbA1c, blood pressure, LDL-C)
Number of subjects: 20412
Study 34397713 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib for 12 weeks
Number of subjects: 20
Study 34397713 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib for 24 weeks
Number of subjects: 20
Study 34397719 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (Diphereline, 3.75 mg intramuscular injection once every 28 days for up to 24 weeks) - Group A (1-3 injections)
Number of subjects: 384
Study 34397719 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (Diphereline, 3.75 mg intramuscular injection once every 28 days for up to 24 weeks) - Group B (4-6 injections)
Number of subjects: 384
Study 34397987 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin (10 mg once daily)
Number of subjects: 100
Study 34397987 — intervention group
Group type: COMPARATOR
Intervention: sitagliptin (100 mg once daily)
Number of subjects: 100
Study 34397987 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin
Number of subjects: 100
Study 34397987 — intervention group
Group type: COMPARATOR
Intervention: sitagliptin
Number of subjects: 100
Study 34397987 — intervention group
Group type: COMPARATOR
Intervention: empagliflozin vs. sitagliptin
Number of subjects: 100
Study 34398056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg)
Number of subjects: 49
Study 34398061 — intervention group
Group type: EXPERIMENTAL
Intervention: High step (16,048 ± 725 steps per day)
Number of subjects: 16
Study 34398061 — intervention group
Group type: COMPARATOR
Intervention: Low step (4767 ± 377 steps per day)
Number of subjects: 16
Study 34398099 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and parenteral antimicrobial therapy without wound débridement
Number of subjects: 0
Study 34398099 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antimicrobial therapy in combination with wound débridement
Number of subjects: 0
Study 34398099 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional and emerging antibiofilm therapies
Number of subjects: 0
Study 34398099 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial products to manage wound biofilm infection
Number of subjects: 0
Study 34398238 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-7 (IL-7) administration to ICL patients
Number of subjects: 0
Study 34398238 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 34398492 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest
Number of subjects: 272
Study 34398492 — intervention group
Group type: EXPERIMENTAL
Intervention: NashTest-2
Number of subjects: 272
Study 34398492 — intervention group
Group type: EXPERIMENTAL
Intervention: SteatoTest-2
Number of subjects: 272
Study 34398492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballooning
Number of subjects: 272
Study 34398492 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobular inflammation
Number of subjects: 272
Study 34398557 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel drugs targeting pathways involved in B-cell receptor signaling
Number of subjects: 0
Study 34398557 — intervention group
Group type: EXPERIMENTAL
Intervention: Agents that inhibit targets of the leukemia microenvironment
Number of subjects: 0
Study 34398588 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Surgical Stereotactic Radiotherapy (SRT)
Number of subjects: 0
Study 34398588 — intervention group
Group type: COMPARATOR
Intervention: Surgically Targeted Radiation Therapy (STaRT) with GammaTile
Number of subjects: 0
Study 34398631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower perceived social support from significant others and friends
Number of subjects: 63
Study 34398631 — intervention group
Group type: COMPARATOR
Intervention: Perceived social support from family
Number of subjects: 63
Study 34398631 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social support from friends
Number of subjects: 63
Study 34398787 — intervention group
Group type: EXPERIMENTAL
Intervention: TOGETHERCare mobile app
Number of subjects: 7
Study 34398907 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (FQ)
Number of subjects: 51898
Study 34398907 — intervention group
Group type: COMPARATOR
Intervention: Negative control exposures (NCE)
Number of subjects: 51898
Study 34398907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure period
Number of subjects: 51898
Study 34398971 — intervention group
Group type: EXPERIMENTAL
Intervention: Chidamide-cladribine-gemcitabine-busulfan (ChiCGB) combination as conditioning therapy after transplantation with autologous peripheral stem cells.
Number of subjects: 105
Study 34398971 — intervention group
Group type: EXPERIMENTAL
Intervention: Chidamide-cladribine-gemcitabine-busulfan (ChiCGB) combination as conditioning therapy.
Number of subjects: 105
Study 34399137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis smoking
Number of subjects: 14
Study 34399432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OACs)
Number of subjects: 11972
Study 34399432 — intervention group
Group type: COMPARATOR
Intervention: No AF (control group)
Number of subjects: 11972
Study 34399717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour (measured using ActivPal®)
Number of subjects: 257
Study 34399731 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine health checks conducted by school doctors
Number of subjects: 1341
Study 34399731 — intervention group
Group type: EXPERIMENTAL
Intervention: Children classified as needing a health check
Number of subjects: 1341
Study 34399731 — intervention group
Group type: EXPERIMENTAL
Intervention: Study questionnaires assessing need for health check
Number of subjects: 1341
Study 34399736 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP provision
Number of subjects: 2567
Study 34399737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy (DT) intervention
Number of subjects: 37
Study 34399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache
Number of subjects: 224
Study 34399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea/vomiting
Number of subjects: 224
Study 34399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck pain
Number of subjects: 224
Study 34399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac arrest
Number of subjects: 224
Study 34399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Persisting unconsciousness
Number of subjects: 224
Study 34399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Inability to stand up
Number of subjects: 224
Study 34399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech difficulty
Number of subjects: 224
Study 34399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweating
Number of subjects: 224